CANCER BIOLOGY PROGRAM Lisa M. Coussens, PhD, and Melissa Wong, PhD, Program Co-Leaders ABSTRACT Cancer Biology (CB) Program members explore genetic, molecular and cellular mechanisms underlying cancer initiation, progression, and response and resistance to therapy, providing platforms to translate basic science discoveries to clinical care. The program strives to gain insights into therapeutically-targetable pathways in neoplastic and host-derived cells within complex tumor microenvironments that drive malignancy. The program supports the overarching goal of the Knight Cancer Institute to understand the molecular and cellular basis of cancer and to translate these findings into precision clinical care. To accomplish these goals, the program is organized into three research themes: signal transduction (focused on cellular signaling mechanism relevant to homeostatic and neoplastic cell proliferation), carcinogenesis/genetic instability (examining cell intrinsic and extrinsic mechanisms that predispose to cancer, including regulation of cell-cycle checkpoint control, DNA damage and repair, and genetic and epigenetic alterations), and the tumor microenvironment (investigating mesenchymal support, immune, and vascular cell interactions with neoplastic cells). Program co-leader Melissa Wong, Ph.D., is an expert in stem cell biology, particularly in colorectal, breast and pancreas cancers. Co-leader Lisa M. Coussens, Ph.D., is an expert in the biology of microenvironmental regulation of solid tumorigenesis, with emphasis on cutaneous squamous, breast and pancreatic cancer. The 26 members are drawn from five basic science departments, three clinical departments or divisions in the OHSU School of Medicine, and four institutes affiliated with OHSU. Annual direct-cost funding as of January 2016 amounted to $14,666,464 (total cost), of which $6,250,223 (total cost) was from the NCI and $11,592,453 (total cost) was peer-reviewed. The discoveries made in this program have resulted in 202 publications, of which 12% are intra-programmatic collaborations and 28% are inter-programmatic collaborations, and 56% are inter-institutional.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA069533-20
Application #
9640140
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
20
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6

Showing the most recent 10 out of 277 publications